The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Efficacy, Safety, and Tolerability of Once-Daily Niacin for the Treatment of Dyslipidemia Associated With Type 2 Diabetes<subtitle>Results of the Assessment of Diabetes Control and Evaluation of the Efficacy of Niaspan Trial</subtitle>
Abstract
BACKGROUND: Diabetic dyslipidemia is characterized by high triglyceride levels; low high-density lipoprotein cholesterol levels; small, dense low-density lipoprotein particles; and high free fatty acid levels. Niacin reduces concentrations of triglyceride-rich and small low-density lipoprotein particles while increasing high-density lipoprotein cholesterol levels. It also lowers levels of free fatty acids and lipoprotein(a). However, the use of niacin in patients with diabetes has been discouraged because high doses can worsen glycemic control. We evaluated the efficacy and safety of once-daily extended-release (ER) niacin in patients with diabetic dyslipidemia. METHODS: During a 16-week, double-blind, placebo-controlled trial, 148 patients were randomized to placebo (n = 49) or 1000 (n = 45) or 1500 mg/d (n = 52) of ER niacin. Sixty-nine patients (47%) were also receiving concomitant therapy with statins. RESULTS: Dose-dependent increases in high-density lipoprotein cholesterol levels (+19% to +24% [P<.05] vs placebo for both niacin dosages) and reductions in triglyceride levels (-13% to -28% [P<.05] vs placebo for the 1500-mg ER niacin) were observed. Baseline and week 16 values for glycosylated hemoglobin levels were 7.13% and 7.11%, respectively, in the placebo group; 7.28% and 7.35%, respectively, in the 1000-mg ER niacin group (P=.16 vs placebo); and 7.2% and 7.5%, respectively, in the 1500-mg ER niacin group (P=.048 vs placebo). Four patients discontinued participation because of inadequate glucose control. Rates of adverse event rates other than flushing were similar for the niacin and placebo groups. Four patients discontinued participation owing to flushing (including 1 receiving placebo). No hepatotoxic effects or myopathy were observed. CONCLUSION: Low doses of ER niacin (1000 or 1500 mg/d) are a treatment option for dyslipidemia in patients with type 2 diabetes.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Lower doses of nicotinic acid lessen this risk.”
From Diagnosis and Management of the Metabolic Syndrome: An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement (2005) · cites this paper as [169]
In the citing paper
“It can significantly increase blood glucose at high doses, but recent studies demonstrate that at modest doses (750–2,000 mg/day), significant improvements in LDL cholesterol, HDL cholesterol, and triglyceride levels are accompanied by only modest changes in glucose that are generally amenable to adjustment of diabetes therapy (205,206).”
From Standards of Medical Care in Diabetes—2009 (2009) · cites this paper as [206]
Citations
Cites
Sacks, F. M., Pfeffer, M. A., Moye, L. A., Rouleau, J. L., Rutherford, J. D., Cole, T. G., Brown, L., Warnica, J. W., Arnold, J. M. O., Wun, C.-C., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199610033351401 · Cited by 7,439
Rubins, H. B., Robins, S. J., Collins, D., Fye, C. L., Anderson, J. W., Elam, M. B., Faas, F. H., Linares, E., Schaefer, E. J., Schectman, G., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199908053410604 · Cited by 3,439
Grundy, S. M., Benjamin, I. J., Burke, G. L., Chait, A., Eckel, R. H., Howard, B. V., Mitch, W., Smith, S. C., & Sowers, J. R. (1999) · Circulation · doi:10.1161/01.cir.100.10.1134 · Cited by 2,698
Self-citationClofibrate and Niacin in Coronary Heart Disease
Stamler, J. (1975) · JAMA · doi:10.1001/jama.1975.03240160024021 · Cited by 1,750
Pyörälä, K., Pedersen, T. R., Kjekshus, J., Faergeman, O., Olsson, A. G., Thorgeirsson, G., & The Scandinavian Simvastatin Survival Study (4S) Group (1997) · Diabetes Care · doi:10.2337/diacare.20.4.614 · Cited by 1,623 · cited 1×
“60 Missing 0 1 (2) 0 Added new drug/increased dose‡ 8 (16) 11 (24) 15 (29) .”
Relation of Gemfibrozil Treatment and Lipid Levels With Major Coronary Events
Robins, S. J., Collins, D. E., Wittes, J. T., Papademetriou, V., DEEDWANIA, P. C., Schaefer, E. J., McNamara, J. R., Kashyap, M. L., Hershman, J. M., WEXLER, L. F., et al. (2001) · JAMA · doi:10.1001/jama.285.12.1585 · Cited by 917
Diabetes and atherosclerosis: An epidemiologic view
Pyörälà, K., Laakso, M., & Uusitupa, M. I. J. (1987) · Diabetes/Metabolism Reviews · doi:10.1002/dmr.5610030206 · Cited by 912
Królewski, A. S., Kosinski, E. J., Warram, J. H., Leland, O. S., Busick, E. J., Asmal, A. C., Rand, L. I., Christlieb, A. R., Bradley, R. F., & Kahn, C. R. (1987) · The American Journal of Cardiology · doi:10.1016/0002-9149(87)91086-1 · Cited by 654
Coronary Heart Disease Incidence in NIDDM Patients In The Helsinki Heart Study
Koskinen, P., Mänttäri, M., Manninen, V., Huttunen, J. K., Heinonen, O. P., & Frick, M. H. (1992) · Diabetes Care · doi:10.2337/diacare.15.7.820 · Cited by 509
Elam, M. B., Hunninghake, D. B., Davis, K. B., Garg, R., Johnson, C. W., Egan, D., Kostis, J. B., Sheps, D. S., Brinton, E. A., & for the ASTEROID Investigators (2000) · JAMA · doi:10.1001/jama.284.10.1263 · Cited by 509
Flagged first, then by citations
Cited by
Sorted by citations
Grundy, S. M., Cleeman, J. I., Daniels, S. R., Donato, K. A., Eckel, R. H., Franklin, B. A., Gordon, D. J., Krauss, R. M., Savage, P. J., Smith, S. C., et al. (2005) · Circulation · doi:10.1161/circulationaha.105.169404 · Cited by 11,961
Self-citationStone, N. J., Robinson, J. G., Lichtenstein, A. H., Bairey Merz, C. N., Blum, C. B., Eckel, R. H., Goldberg, A. C., Gordon, D., Levy, D., Lloyd-Jones, D. M., et al. (2014) · Circulation · doi:10.1161/01.cir.0000437738.63853.7a · Cited by 7,081
Eckel, R. H., Alberti, K., Grundy, S. M., & Zimmet, P. (2010) · The Lancet · doi:10.1016/s0140-6736(09)61794-3 · Cited by 6,317
Self-citationEckel, R. H., Grundy, S. M., & Zimmet, P. (2005) · The Lancet · doi:10.1016/s0140-6736(05)66378-7 · Cited by 5,755
Self-citationStandards of medical care in diabetes—2014
American Diabetes Association (2014) · Diabetes Care · doi:10.2337/dc14-s014 · Cited by 4,572
Standards of medical care in diabetes—2013
American Diabetes Association (2013) · Diabetes Care · doi:10.2337/dc13-s011 · Cited by 4,369
Stone, N. J., Robinson, J. G., Lichtenstein, A. H., Bairey Merz, C. N., Blum, C. B., Eckel, R. H., Goldberg, A. C., Gordon, D., Levy, D., Lloyd-Jones, D. M., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.11.002 · Cited by 3,845
Standards of medical care in diabetes 2010
American Diabetes Association (2010) · Diabetes Care · doi:10.2337/dc10-s011 · Cited by 3,470
Standards of medical care in diabetes—2011
American Diabetes Association (2011) · Diabetes Care · doi:10.2337/dc11-s011 · Cited by 2,880
Type 2 diabetes: principles of pathogenesis and therapy
Stumvoll, M., Goldstein, B. J., & van Haeften, T. W. (2005) · The Lancet · doi:10.1016/s0140-6736(05)61032-x · Cited by 2,662
Standards of Medical Care in Diabetes—2012
(2012) · Diabetes Care · doi:10.2337/dc12-s011 · Cited by 2,240
Standards of Medical Care in Diabetes—2009
American Diabetes Association (2009) · Diabetes Care · doi:10.2337/dc09-s013 · Cited by 2,167
Cornier, M.-A., Dabelea, D., Hernandez, T. L., Lindstrom, R. C., Steig, A. J., Stob, N. R., Van Pelt, R. E., Wang, H., & Eckel, R. H. (2008) · Endocrine Reviews · doi:10.1210/er.2008-0024 · Cited by 2,162
A comprehensive review on metabolic syndrome
Kaur, J. (2014) · Cardiology Research and Practice · doi:10.1155/2014/943162 · Cited by 1,889
RetractedStandards of Medical Care in Diabetes–2006
American Diabetes Association (2006) · Diabetes Care · doi:10.2337/diacare.29.s1.06.s4 · Cited by 1,885
Creager, M. A., Lüscher, T. F., of, P. W. T. A., Cosentino, F., & Beckman, J. A. (2003) · Circulation · doi:10.1161/01.cir.0000091257.27563.32 · Cited by 1,675
Clinical Practice Guidelines for Multiple Endocrine Neoplasia Type 1 (MEN1)
Thakker, R. V., Newey, P. J., Walls, G. V., Bilezikian, J. P., Dralle, H., Ebeling, P. R., Melmed, S. K., Sakurai, A., Tonelli, F., & Brandi, M. L. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-1230 · Cited by 1,500
Standards of Medical Care in Diabetes 2014
(2014) · Majmaah Journal of Health Sciences · doi:10.12816/0004790 · Cited by 1,478
Standards of Medical Care in Diabetes—2008
American Diabetes Association (2008) · Diabetes Care · doi:10.2337/dc08-s012 · Cited by 1,377
Chapman, M. J., Ginsberg, H. N., Amarenco, P., Andreotti, F., Borén, J., Catapano, A. L., Descamps, O. S., Fisher, E., Kovanen, P. T., Kuivenhoven, J. A., et al. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr112 · Cited by 1,227
Management Guidelines for Children with Thyroid Nodules and Differentiated Thyroid Cancer
Francis, G. L., Waguespack, S. G., Bauer, A. J., Angelos, P., Benvenga, S., Cerutti, J. M., Dinauer, C., Hamilton, J. K., HAY, I. D., Luster, M., et al. (2015) · Thyroid · doi:10.1089/thy.2014.0460 · Cited by 1,273
Grundy, S. M. (2010) · Springer eBooks · doi:10.1007/978-1-4419-5839-6_1 · Cited by 1,227
Self-citationOxidative stress, insulin resistance, dyslipidemia and type 2 diabetes mellitus
Tangvarasittichai, S. (2015) · World Journal of Diabetes · doi:10.4239/wjd.v6.i3.456 · Cited by 1,284
Nowy rok, stare problemy, ale i nowe możliwości
Czupryniak, L. (2014) · Via Medica Journals · Cited by 1,192
Standards of Medical Care in Diabetes—2007
American Diabetes Association (2007) · Diabetes Care · doi:10.2337/dc07-s004 · Cited by 1,190
Jellinger, P. S., Handelsman, Y., Rosenblit, P. D., Bloomgarden, Z. T., Fonseca, V. A., Garber, A. J., Grunberger, G., Guerin, C. K., Bell, D. S. H., Mechanick, J. I., et al. (2017) · Endocrine Practice · doi:10.4158/ep171764.appgl · Cited by 1,094
Adiels, M., Olofsson, S.-O., Taskinen, M.-R., & Borén, J. (2008) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.107.160192 · Cited by 820
Lipids and Lipoproteins in Patients With Type 2 Diabetes
Krauss, R. M. (2004) · Diabetes Care · doi:10.2337/diacare.27.6.1496 · Cited by 764
Fouque, D. P., Vennegoor, M. A., ter Wee, P. M., Wanner, C., Başçı, A., Canaud, B., Haage, P., Könner, K., Kooman, J. P., Martín‐Malo, A., et al. (2007) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfm020 · Cited by 723
Lipoprotein Management in Patients With Cardiometabolic Risk
Brunzell, J. D., Davidson, M. H., Furberg, C. D., Goldberg, R. B., Howard, B. V., Stein, J. H., & Witztum, J. L. (2008) · Diabetes Care · doi:10.2337/dc08-9018 · Cited by 716
Standards of Medical Care in Diabetes
(2004) · Diabetes Care · doi:10.2337/diacare.27.2007.s15 · Cited by 688
HPS2-THRIVE Collaborative Group, Haynes, R., Jiang, L., Hopewell, J. C., Li, J., Chen, F., Parish, S., Landray, M. J., Collins, R., Armitage, J., et al. (2013) · European Heart Journal · doi:10.1093/eurheartj/eht055 · Cited by 676
Standards of Medical Care for Patients With Diabetes Mellitus
American Diabetes Association (2003) · Diabetes Care · doi:10.2337/diacare.26.2007.s33 · Cited by 614
Nicotinic acid: the broad‐spectrum lipid drug. A 50th anniversary review
Carlson, L. A. (2005) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2005.01528.x · Cited by 591
Dubé, M. P., Stein, J. H., Aberg, J. A., Fichtenbaum, C. J., Gerber, J. G., Tashima, K. T., Henry, W. K., Currier, J. S., Sprecher, D. L., & Glesby, M. J. (2003) · Clinical Infectious Diseases · doi:10.1086/378131 · Cited by 578
Jellinger, P. S., Smith, D. A., Mehta, A., Ganda, O. P., Handelsman, Y., Rodbard, H. W., Shepherd, M. D., & Seibel, J. A. (2012) · Endocrine Practice · doi:10.4158/ep.18.s1.1 · Cited by 533
Lipoprotein Management in Patients With Cardiometabolic Risk
Brunzell, J. D., Davidson, M. H., Furberg, C. D., Goldberg, R. B., Howard, B. V., Stein, J. H., & Witztum, J. L. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.02.034 · Cited by 526
Carr, M. C., & Brunzell, J. D. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-0432 · Cited by 493
High-sensitivity C-reactive protein
Bassuk, S. S., Rifai, N., & Ridker, P. M. (2004) · Current Problems in Cardiology · doi:10.1016/s0146-2806(04)00074-x · Cited by 493
Fruchart, J.-C., Sacks, F., Hermans, M. P., Assmann, G., Brown, W. V., Ceska, R., Chapman, M. J., Dodson, P. M., Fioretto, P., Ginsberg, H. N., et al. (2008) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2008.10.002 · Cited by 463
Diagnosis and management of the metabolic syndrome
Grundy, S. M., Cleeman, J. I., Daniels, S. R., Donato, K. A., Eckel, R. H., Franklin, B. A., Gordon, D. J., Krauss, R. M., Savage, P. J., Smith, S. C., et al. (2005) · Current Opinion in Cardiology · doi:10.1097/01.hco.0000200416.65370.a0 · Cited by 437
Self-citationHigh-Density Lipoprotein as a Therapeutic Target: A Systematic Review
Singh, I. M., Shishehbor, M. H., & Ansell, B. J. (2007) · JAMA · doi:10.1001/jama.298.7.786 · Cited by 468
Lüscher, T. F., Creager, M. A., Beckman, J. A., & Cosentino, F. (2003) · Circulation · doi:10.1161/01.cir.0000089189.70578.e2 · Cited by 395
Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds
Birjmohun, R. S., Hutten, B. A., Kastelein, J. J. P., & Stroes, E. S. G. (2005) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2004.10.031 · Cited by 429
Nicotinic Acid: Pharmacological Effects and Mechanisms of Action
Gille, A., Bodor, E. T., Ahmed, K., & Offermanns, S. (2007) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.48.113006.094746 · Cited by 316
Reduction in C-reactive protein through cardiac rehabilitation and exercise training
Milani, R. V., Lavie, C. J., & Mehra, M. R. (2004) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2003.10.041 · Cited by 302
I Diretriz Brasileira de Diagnóstico e Tratamento da Síndrome Metabólica
de Carvalho, M. H. C., Mancini, M. C., de Melo, M. E., Bahia, L., Negrão, C. E., de Matos, L. D. N. J., Sanjuliani, A. F., Kohlmann, O., Oliveira, J. E. P. D., Lerário, A. C., et al. (2005) · Arquivos Brasileiros de Cardiologia · doi:10.1590/s0066-782x2005000700001 · Cited by 305
Dyslipidemia in Type 2 Diabetes: Prevalence, Pathophysiology, and Management
Chehade, J. M., Gladysz, M., & Mooradian, A. D. (2013) · Drugs · doi:10.1007/s40265-013-0023-5 · Cited by 308
Brunzell, J. D. (2007) · New England Journal of Medicine · doi:10.1056/nejmcp070061 · Cited by 268
Safety considerations with niacin therapy
Guyton, J. R., & Bays, H. E. (2007) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2006.11.018 · Cited by 269
Biological Properties of Vitamins of the B-Complex, Part 1: Vitamins B1, B2, B3, and B5
Hrubša, M., Siatka, T., Najmanová, I., Vopršalová, M., Krčmová, L. K., Matoušová, K., Javorská, L., Macáková, K., Mercolini, L., Remião, F., et al. (2022) · Nutrients · doi:10.3390/nu14030484 · Cited by 284
Fruchart, J.-C., Sacks, F. M., Hermans, M. P., Assmann, G., Brown, W. V., Ceska, R., Chapman, M. J., Dodson, P. M., Fioretto, P., Ginsberg, H. N., et al. (2008) · Diabetes and Vascular Disease Research · doi:10.3132/dvdr.2008.046 · Cited by 260
Chapman, M. J., Assmann, G., Fruchart, J., Shepherd, J., & Sirtori, C. R. (2004) · Current Medical Research and Opinion · doi:10.1185/030079904125004402 · Cited by 257
Effects of High-Dose Modified-Release Nicotinic Acid on Atherosclerosis and Vascular Function
Lee, J. M. S., Robson, M. D., Yu, L.-M., Shirodaria, C. C., Cunnington, C., Kylintireas, I., Digby, J. E., Bannister, T., Handa, A., Wiesmann, F., et al. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.06.036 · Cited by 246
Managing Abnormal Blood Lipids
Fletcher, B. J., Berra, K. A., Ades, P., Braun, L. T., Burke, L. E., Durstine, J. L., Fair, J. M., Fletcher, G. F., Goff, D. C., Hayman, L. L., et al. (2005) · Circulation · doi:10.1161/circulationaha.105.169180 · Cited by 238
Whitney, E. J., Krasuski, R. A., Personius, B. E., Michalek, J. E., Maranian, A. M., Kolasa, M. W., Monick, E. A., Brown, B. G., & Gotto, A. M. (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-142-2-200501180-00008 · Cited by 233
High-Density Lipoprotein and Coronary Heart Disease
Natarajan, P., Ray, K. K., & Cannon, C. P. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.01.008 · Cited by 231
Niacin and fibrates in atherogenic dyslipidemia: pharmacotherapy to reduce cardiovascular risk
Chapman, M. J., Redfern, J. S., McGovern, M. E., & Giral, P. (2010) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2010.01.008 · Cited by 227
New Perspectives on the Use of Niacin in the Treatment of Lipid Disorders
McKenney, J. M. (2004) · Archives of Internal Medicine · doi:10.1001/archinte.164.7.697 · Cited by 217
Hypertriglyceridemia secondary to obesity and diabetes
Subramanian, S., & Chait, A. (2011) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2011.10.003 · Cited by 205
Mikhailidis, D. P., Elisaf, M., Rizzo, M., Berneis, K. K., Griffin, B. A., Zambon, A., Athyros, V. G., Graaf, J. D., März, W., Parhofer, K. G., et al. (2011) · Current Vascular Pharmacology · doi:10.2174/157016111796642661 · Cited by 199
Fabbrini, E., Mohammed, B. S., Korenblat, K. M., Magkos, F., McCrea, J., Patterson, B. W., & Klein, S. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2622 · Cited by 192
Niacin therapy in atherosclerosis
Meyers, C. D., Kamanna, V. S., & Kashyap, M. L. (2004) · Current Opinion in Lipidology · doi:10.1097/00041433-200412000-00006 · Cited by 176
HDL dysfunction in diabetes: causes and possible treatments
Farbstein, D., & Levy, A. P. (2012) · Expert Review of Cardiovascular Therapy · doi:10.1586/erc.11.182 · Cited by 178
Pharmacotherapy for dyslipidaemia ? current therapies and future agents
Bays, H. E., & Stein, E. A. (2003) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.4.11.1901 · Cited by 173
Inflammation, Hypertension, and the Metabolic Syndrome
Grundy, S. M. (2003) · JAMA · doi:10.1001/jama.290.22.3000 · Cited by 170
Self-citationKinlay, S. (2007) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.01.083 · Cited by 164
AJC Editor's Consensus: Psoriasis and Coronary Artery Disease
Friedewald, V. E., Cather, J. C., Gelfand, J. M., Gordon, K. B., Gibbons, G. H., Grundy, S. M., Jarratt, M., Krueger, J. G., Ridker, P. M., Stone, N. J., et al. (2008) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2008.10.004 · Cited by 163
Self-citationDyslipidemia and cardiovascular risk: the importance of early prevention
Miller, M. J. (2009) · QJM · doi:10.1093/qjmed/hcp065 · Cited by 165
Statin-fibrate combination therapy for hyperlipidaemia: a review
Wierzbicki, A. S., Mikhailidis, D. P., Wray, R., Schachter, M., Cramb, R., Simpson, W. G., & Byrne, C. D. (2003) · Current Medical Research and Opinion · doi:10.1185/030079903125001668 · Cited by 156
Targeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels
Hausenloy, D. J., & Yellon, D. M. (2008) · Heart · doi:10.1136/hrt.2007.125401 · Cited by 151
Sahebkar, A., Reiner, Ž., Simental‐Mendía, L. E., Ferretti, G., & Cicero, A. F. G. (2016) · Metabolism · doi:10.1016/j.metabol.2016.08.007 · Cited by 148
REVIEW: Efficacy and Mechanisms of Action of Statins in the Treatment of Diabetic Dyslipidemia
Ginsberg, H. N. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-2084 · Cited by 146
Niacin therapy in atherosclerosis
Meyers, C. D., Kamanna, V. S., & Kashyap, M. L. (2005) · Current Opinion in Internal Medicine · doi:10.1097/00132980-200502000-00005 · Cited by 139
Nitric Oxide: Considerations for the Treatment of Ischemic Stroke
Terpolilli, N. A., Moskowitz, M. A., & Plesnila, N. (2012) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2012.12 · Cited by 139
Nicotinic acid: an old drug with a promising future
Bodor, E. T., & Offermanns, S. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707528 · Cited by 136
Role of Prescription Omega‐3 Fatty Acids in the Treatment of Hypertriglyceridemia
McKenney, J. M., & Sica, D. A. (2007) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.27.5.715 · Cited by 131
Lip, G. Y. H., Barnett, A. H., Bradbury, A. W., Cappuccio, F. P., Gill, P. S., Hughes, E. A., Imray, C., Jolly, K. B., & Patel, K. (2007) · Journal of Human Hypertension · doi:10.1038/sj.jhh.1002126 · Cited by 132
Approach to lipoprotein management in 2001 National Cholesterol Guidelines
Grundy, S. M. (2002) · The American Journal of Cardiology · doi:10.1016/s0002-9149(02)02631-0 · Cited by 128
Self-citationNiacin for primary and secondary prevention of cardiovascular events
Schandelmaier, S., Briel, M., Saccilotto, R. T., Olu, K. K., Arpagaus, A., Hemkens, L. G., & Nordmann, A. J. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009744.pub2 · Cited by 120
Lipids and lipid management in diabetes
Jaiswal, M., Schinske, A., & Pop‐Busui, R. (2013) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2013.12.001 · Cited by 118
Dyslipidemia in type 2 diabetes
Krauss, R. M., & Siri, P. W. (2004) · Medical Clinics of North America · doi:10.1016/j.mcna.2004.04.004 · Cited by 119
Atherogenic dyslipidemia associated with metabolic syndrome and insulin resistance
Grundy, S. M. (2006) · Clinical cornerstone · doi:10.1016/s1098-3597(06)80005-0 · Cited by 116
Self-citationMaccubbin, D., Bays, H. E., OLSSON, A. G., Elinoff, V., Elis, A., Mitchel, Y., Sirah, W., Betteridge, A., Reyes, R., Yu, Q., et al. (2008) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2008.01938.x · Cited by 115
Lipid Management to Reduce Cardiovascular Risk: A New Strategy Is Required
Superko, H. R., & King, S. B. (2008) · Circulation · doi:10.1161/circulationaha.106.667428 · Cited by 112
Effects of Niacin on Glucose Control in Patients With Dyslipidemia
Goldberg, R. B., & Jacobson, T. A. (2008) · Mayo Clinic Proceedings · doi:10.4065/83.4.470 · Cited by 112
Zhao, X.-Q., Morse, J. S., Dowdy, A. A., Heise, N., DeAngelis, D., Frohlich, J. J., Chait, A., Albers, J. J., & Brown, B. G. (2004) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2003.10.009 · Cited by 112
Thoenes, M., Oguchi, A., Nagamia, S. H., Vaccari, C. S., Hammoud, R., Umpierrez, G. E., & Khan, B. V. (2007) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2007.01597.x · Cited by 108
Dyslipidemia in Visceral Obesity
Chan, D. C., Barrett, P. H. R., & Watts, G. F. (2004) · American Journal of Cardiovascular Drugs · doi:10.2165/00129784-200404040-00004 · Cited by 111
Lipoprotein (a) and diabetes mellitus
Lamina, C., & Ward, N. C. (2022) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2022.04.016 · Cited by 115
Regulation of NAD+ metabolism in aging and disease
Chu, X., & Raju, R. P. (2021) · Metabolism · doi:10.1016/j.metabol.2021.154923 · Cited by 107
Kendall, D. M., & Harmel, A. P. (2002) · PubMed · Cited by 105
Poynten, A. M., Gan, S. K., Kriketos, A. D., O’Sullivan, A., Kelly, J. J., Ellis, B. A., Chisholm, D. J., & Campbell, L. V. (2003) · Metabolism · doi:10.1016/s0026-0495(03)00030-1 · Cited by 104
Comparative effects of lipid-lowering therapies
Davidson, M. H., & Toth, P. P. (2004) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2004.04.007 · Cited by 106
Shepherd, J., Betteridge, J. D., Gaal, L. V., & Panel, O. B. O. A. E. C. (2005) · Current Medical Research and Opinion · doi:10.1185/030079905x43677 · Cited by 100
A Practical “ABCDE” Approach to the Metabolic Syndrome
Blaha, M. J., Bansal, S., Rouf, R., Golden, S. H., Blumenthal, R. S., & DeFilippis, A. P. (2008) · Mayo Clinic Proceedings · doi:10.4065/83.8.932 · Cited by 96
Watts, G. F., & Karpe, F. (2011) · Heart · doi:10.1136/hrt.2010.204990 · Cited by 97
Bays, H., Davidson, M., Jones, M. R., & Abby, S. L. (2006) · American Journal of Cardiology · doi:10.1016/j.amjcard.2005.11.039 · Cited by 103
Clinical importance and therapeutic modulation of small dense low-density lipoprotein particles
Gazi, I. F., Tsimihodimos, V., Tselepis, A. D., Elisaf, M., & Mikhailidis, D. P. (2006) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.7.1.53 · Cited by 98
Effects of polydatin from Polygonum cuspidatum on lipid profile in hyperlipidemic rabbits
Xing, W.-W., Wu, J.-Z., Jia, M., Du, J., Zhang, H., & Qin, L. (2008) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2008.06.035 · Cited by 100
Metadata
- Authors
- Grundy, S. M.
- Affiliations
- The University of Texas at Austin (US)
- Corresponding author
- Grundy, Scott M.
- ORCID
- Grundy, Scott M.
- Venue
- Archives of Internal Medicine
- Publisher
- American Medical Association (AMA)
- Published
- 2002-07-22
- Volume
- 162
- Issue
- 14
- Pages
- 1568
- ISSN
- 0003-9926 (ISSN-L)
- OpenAlex
- W2119065130
- Cited by
- 551
- References
- 21
- Citations by year
- 2026: 2 · 2025: 2 · 2024: 4 · 2023: 3 · 2022: 5 · 2021: 6 · 2020: 8 · 2019: 5 · 2018: 3 · 2017: 5 · 2016: 6 · 2015: 16 · 2014: 14 · 2013: 31 · 2012: 28
- FWCI
- 50.60
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Archives of Internal Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Keywords
- nicotinic acid, extended-release niacin, diabetic dyslipidemia, type 2 diabetes, hypertriglyceridemia, HDL cholesterol, triglycerides, glycemic control, statin combination therapy, lipoprotein(a), drug safety and tolerability, dose-response relationship, hepatotoxicity, myopathy, HbA1c, small dense LDL
- MeSH terms
- Adult, Aged, Hypolipidemic Agents, Blood Glucose, C-Reactive Protein, Diabetes Mellitus, Type 2, Dose-Response Relationship, Drug, Double-Blind Method, Female, Follow-Up Studies, Humans, Hyperlipidemias, Cholesterol, HDL, Cholesterol, LDL, Male, Middle Aged, Niacin, Triglycerides, United States, Biomarkers, Body Mass Index, Treatment Outcome, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Endpoint Determination
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
